These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

466 related items for PubMed ID: 1912029

  • 41. The incidence of thrombotic and hemorrhagic disorders in association with extreme thrombocytosis: an analysis of 129 cases.
    Buss DH, Stuart JJ, Lipscomb GE.
    Am J Hematol; 1985 Dec; 20(4):365-72. PubMed ID: 3865532
    [Abstract] [Full Text] [Related]

  • 42. The chronic myeloproliferative disorders: clonality and clinical heterogeneity.
    Spivak JL.
    Semin Hematol; 2004 Apr; 41(2 Suppl 3):1-5. PubMed ID: 15190515
    [Abstract] [Full Text] [Related]

  • 43. The 2001 World Health Organization and updated European clinical and pathological criteria for the diagnosis, classification, and staging of the Philadelphia chromosome-negative chronic myeloproliferative disorders.
    Michiels JJ, De Raeve H, Berneman Z, Van Bockstaele D, Hebeda K, Lam K, Schroyens W.
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):307-40. PubMed ID: 16810609
    [Abstract] [Full Text] [Related]

  • 44. Generation of arachidonic acid metabolites from stimulated whole blood in patients with chronic myeloproliferative disorders.
    Parise P, Huybrechts E, Grasselli S, Falcinelli F, Nenci GG, Gresele P, Vermylen J.
    Acta Haematol; 1991 Jun; 85(2):88-92. PubMed ID: 1902615
    [Abstract] [Full Text] [Related]

  • 45. Current management in polycythemia vera.
    Gilbert HS.
    Semin Hematol; 2001 Jan; 38(1 Suppl 2):25-8. PubMed ID: 11242599
    [Abstract] [Full Text] [Related]

  • 46. Thrombosis and risk factors in female patients with a rare acquired thrombophilia: chronic myeloproliferative disorder - polycythaemia vera and essential thrombocythaemia.
    Pósfai É, Marton I, Kiss-László Z, Kotosz B, Széll M, Borbényi Z.
    Eur Rev Med Pharmacol Sci; 2014 Jan; 18(24):3810-8. PubMed ID: 25555871
    [Abstract] [Full Text] [Related]

  • 47. Essential thrombocythemia in young adults: major thrombotic complications and complications during pregnancy--a follow-up study in 68 patients.
    Randi ML, Rossi C, Fabris F, Girolami A.
    Clin Appl Thromb Hemost; 2000 Jan; 6(1):31-5. PubMed ID: 10726046
    [Abstract] [Full Text] [Related]

  • 48. Bleeding and thrombosis in the myeloproliferative disorders.
    Schafer AI.
    Blood; 1984 Jul; 64(1):1-12. PubMed ID: 6375757
    [Abstract] [Full Text] [Related]

  • 49. A clinical update in polycythemia vera and essential thrombocythemia.
    Tefferi A, Solberg LA, Silverstein MN.
    Am J Med; 2000 Aug 01; 109(2):141-9. PubMed ID: 10967156
    [Abstract] [Full Text] [Related]

  • 50. [Thrombosis in myeloproliferative neoplasms].
    Asakura H.
    Rinsho Ketsueki; 2018 Aug 01; 59(8):1034-1041. PubMed ID: 30185703
    [Abstract] [Full Text] [Related]

  • 51. [Risk factors for recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia].
    Han X, Bai BB, Wang CJ, Zhao S, Chen Y.
    Zhonghua Xue Ye Xue Za Zhi; 2019 Jan 14; 40(1):17-23. PubMed ID: 30704223
    [Abstract] [Full Text] [Related]

  • 52. [The effectiveness of anagrelide treatment in patients with Ph negative myeloproliferative diseases: influence on the incidence of thrombosis in the data from the Registry of patients with essential thrombocythemia and thrombocythemia associated with other myeloproliferative diseases treated with Thromboreductin® to the end of 2012].
    Penka M, Schwarz J, Ovesná P, Cervinek L, Dulíček P, Pospíšilová D, Kissová J, Pavlík T, kolektiv Ceske pracovni skupiny pro myeloproliferativni choroby (CZEMP).
    Vnitr Lek; 2013 Jun 14; 59(6):516-31. PubMed ID: 23808749
    [Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54. The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia.
    Bellucci S, Michiels JJ.
    Semin Thromb Hemost; 2006 Jun 14; 32(4 Pt 2):381-98. PubMed ID: 16810614
    [Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59. [The JAK2 mutation in myeloproliferative disorders: A predictive factor of thrombosis].
    Mahjoub S, Baccouche H, Sahnoun M, Kaabi H, Manai Z, Slama H, Ben Romdhane N.
    Tunis Med; 2015 Jul 14; 93(7):474-7. PubMed ID: 26757507
    [Abstract] [Full Text] [Related]

  • 60. Thrombohaemorrhagic complications in 101 cases of myeloproliferative disorders: relationship to platelet number and function.
    Barbui T, Cortelazzo S, Viero P, Bassan R, Dini E, Semeraro N.
    Eur J Cancer Clin Oncol; 1983 Nov 14; 19(11):1593-9. PubMed ID: 6580171
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 24.